Mar 21 |
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
|
Mar 20 |
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
|
Mar 13 |
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
|
Mar 6 |
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
|
Feb 28 |
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
|
Feb 6 |
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
|
Jan 26 |
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women
|
Jan 23 |
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology
|
Dec 15 |
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine
|
Nov 30 |
Femasys filed to sell 18.11M shares of common stock for holders
|